Can you provide education about trazodone, including its dosing, side effects, precautions, and drug interactions?

Trazodone Education

Trazodone is NOT recommended as a first-line treatment for insomnia, but it is FDA-approved and effective for major depressive disorder at doses of 150-400 mg/day, with lower doses (25-75 mg) commonly used off-label for insomnia despite weak evidence for this indication. 1, 2

FDA-Approved Indication and Dosing

Trazodone is FDA-approved exclusively for major depressive disorder (MDD) in adults 2:

• Starting dose: 150 mg/day in divided doses
• Titration: Increase by 50 mg/day every 3-4 days based on response and tolerability
• Outpatient maximum: 400 mg/day in divided doses
• Inpatient maximum: 600 mg/day (for severely depressed patients)
• Administration: Take shortly after a meal or light snack to maximize effectiveness 2

Important: Trazodone is NOT FDA-approved for insomnia, and its efficacy for this indication is not well established 3.

Off-Label Use for Insomnia (Not Recommended by Guidelines)

Despite widespread clinical use, major sleep medicine guidelines advise AGAINST using trazodone for insomnia 1:

• The 2017 American Academy of Sleep Medicine guideline states: "We suggest that clinicians NOT use trazodone as a treatment for sleep onset or sleep maintenance insomnia" 1
• The 2020 VA/DoD guideline similarly advises against trazodone, noting "low-quality evidence supporting efficacy was outweighed by its adverse effect profile" 4

Evidence gap: Only one study of trazodone 50 mg showed modest improvements in sleep that fell below clinical significance thresholds for sleep latency (10.2 min reduction), total sleep time (21.8 min increase), and wake after sleep onset (7.7 min reduction) 1.

When prescribed off-label for insomnia, typical doses are 25-75 mg at bedtime 5, 6, substantially lower than antidepressant doses.

Mechanism of Action

Trazodone is a multimodal antidepressant with:

• Serotonin antagonism and reuptake inhibition (SARI)
• α1-adrenergic receptor blockade (causes sedation and orthostatic hypotension)
• Histamine H1 receptor antagonism (contributes to sedative effects)
• Minimal anticholinergic activity 5, 6

Side Effects and Safety Concerns

Common Adverse Effects

Patients must be counseled about these risks 1, 2:

• Somnolence/sedation (23% vs 8% placebo) - most common, dose-dependent
• Headache (30% vs 19% placebo)
• Orthostatic hypotension - particularly problematic in elderly; increases fall risk
• Dizziness
• Dry mouth
• Blurred vision 7

Serious Adverse Effects

Priapism: Rare but serious; requires immediate medical attention. Warn male patients explicitly 2.

Cardiac effects:

• Dose-dependent QTc prolongation with risk of ventricular arrhythmias 8
• Use caution in patients with heart disease, QT prolongation, or family history of cardiac arrhythmias 3, 2

Falls risk: Particularly in elderly due to sedation and orthostatic hypotension 8

Suicidal ideation: Black box warning - monitor closely, especially in patients <25 years old during initial treatment 2

Contraindications and Precautions

Absolute contraindications 2:

• Concurrent MAOI use or within 14 days of MAOI discontinuation
• Within 14 days of stopping trazodone before starting an MAOI

Use with caution in 3, 2:

• Depression with suicidal ideation
• Compromised respiratory function (asthma, COPD, sleep apnea)
• Hepatic or heart failure
• Elderly patients (use lower doses)
• Pregnancy or nursing (not recommended)
• Patients <18 years (safety not established)

Screen for bipolar disorder before initiating treatment, as antidepressants can precipitate manic episodes 2.

Drug Interactions

Critical Interactions

CNS depressants and alcohol: Additive sedation and psychomotor impairment - avoid concurrent use 3, 2

CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin):

• Increase trazodone levels
• Action: Consider dose reduction based on tolerability 2

CYP3A4 inducers (e.g., carbamazepine, rifampin, phenytoin):

• Decrease trazodone levels
• Action: Consider dose increase based on therapeutic response 2

Serotonergic drugs (SSRIs, SNRIs, MAOIs, triptans):

• Risk of serotonin syndrome
• Monitor closely for agitation, confusion, tachycardia, hyperthermia 2

Patient Education Essentials

Counsel patients on 2:

1. Treatment expectations: Full antidepressant effect may take 4-6 weeks; sedation occurs immediately
2. Timing: Take shortly after food; if drowsiness occurs, take larger portion of daily dose at bedtime
3. Suicide risk: Report new/worsening depression, suicidal thoughts, agitation, panic attacks, or behavioral changes immediately
4. Discontinuation: Do NOT stop abruptly - taper gradually to avoid withdrawal symptoms 2
5. Avoid alcohol and other CNS depressants
6. Priapism warning for male patients - seek emergency care for prolonged erections
7. Fall precautions: Rise slowly from sitting/lying positions due to orthostatic hypotension risk
8. Driving/machinery: Avoid until effects are known due to sedation

Monitoring Requirements

Initial phase (first 1-2 weeks) 9:

• Assess therapeutic response and adverse effects regularly
• Monitor for suicidal ideation, especially in young adults
• Check for orthostatic hypotension in elderly

Ongoing 3, 9:

• Evaluate effectiveness every few weeks initially
• If no adequate response within 6-8 weeks, modify treatment
• Monitor for dosage escalation needs
• Assess for rebound insomnia if discontinuing

Treatment Duration

For MDD 9, 10:

• First episode: Continue 4-9 months after satisfactory response
• Recurrent depression: Consider longer duration; risk of recurrence is 50% after first episode, 70% after second, 90% after third

Clinical Context and Alternatives

For insomnia, guidelines recommend 3, 4:

1. First-line: Cognitive behavioral therapy for insomnia (CBT-I)
2. Pharmacologic first-line: Short-intermediate acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) or ramelteon
3. Second-line: Low-dose doxepin (3-6 mg) - has better evidence than trazodone for sleep maintenance
4. Trazodone: Only after other options fail or when treating comorbid depression

For depression with insomnia 3, 6: Trazodone may be particularly useful when depression presents with prominent insomnia, anxiety, or psychomotor agitation, as it addresses both conditions simultaneously at antidepressant doses (150-300 mg).

Common Pitfall

The most common error is prescribing trazodone 25-100 mg for "insomnia" without recognizing this is off-label use with weak evidence and significant adverse effects. If insomnia is the primary complaint without depression, FDA-approved hypnotics or low-dose doxepin have stronger evidence 4, 1, 4.